Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038232 | 0.88 | ALDH1A1 (0.37) | MAPTALDH1A1CYP1A2POLBMAPK1 | |
| SCHEMBL6778694 | 0.82 | PDE4D (0.35) | MAPTPOLB | |
| SCHEMBL7035193 | 0.80 | MAOA (0.42) | MAPTALDH1A1L3MBTL1CYP1A2POLB | |
| SCHEMBL7035141 | 0.73 | CYP1A2 (0.38) | MAPTALDH1A1CYP1A2MAPK1 | |
| SCHEMBL7036369 | 0.73 | MTNR1A (0.38) | MAPTALDH1A1CYP1A2 | |
| SCHEMBL9305415 | 0.71 | ALDH1A1 (0.44) | MAPTALDH1A1POLB | |
| SCHEMBL9300556 | 0.71 | MAPT (0.39) | MAPTALDH1A1CYP1A2 | |
| SCHEMBL7038766 | 0.68 | KDM4E (0.46) | MAPTALDH1A1L3MBTL1CYP1A2MAPK1 | |
| SCHEMBL7041805 | 0.66 | TNF (0.43) | MAPTALDH1A1 | |
| SCHEMBL6403829 | 0.56 | BACE1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114445-A1 | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-19 | — | — | US | disclosed |
| US-20030114414-A1 | Methods for synthesizing substituted pyrimidines | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-19 | — | — | US | disclosed |
| WO-2003011297-A1 | N3-SUBSTITUTED 6-ANILINOPYRIMIDINES AND METHODS TO TREAT GRAM-POSITIVE BACTERIAL AND MYCOPLASMAL INFECTIONS | UNIVERSITY OF MASSACHUSETTS (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002102769-A2 | METHODS FOR SYNTHESIZING SUBSTITUTED PYRIMIDINES | UNIVERSITY OF MASSACHUSETTS (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114445-A1 | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections | MPHOSPH6, MRPS18A, PNP | MAPT 2547/4885ALDH1A1 3453/4885ATM 1964/4885 |
| US-20030114414-A1 | Methods for synthesizing substituted pyrimidines | TYMP, NUDT1, TYMS | MAPT 4134/4885ALDH1A1 1403/4885ATM 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.